AAP issues recommendations for pediatric RSV vaccination in 2026-2027 season
New guidelines expand the categories of high-risk children eligible for respiratory syncytial virus (RSV) vaccination and address COVID-19 vaccines for children in two policy statements and accompanying technical reports from the American Academy of Pediatrics (AAP), published online Sept. 2 in Pediatrics.
The American Academy of Pediatrics (AAP) has issued updated recommendations for pediatric RSV vaccination in the 2026-2027 season, expanding the categories of high-risk children eligible for the vaccine. The AAP Committee on Infectious Diseases recommends RSV immunization for all infants younger than 8 months born during or entering their first RSV season, unless they have documented protection from prenatal vaccination.
Additionally, RSV vaccination is recommended for children ages 8 through 19 months at high risk for severe RSV disease who are entering their second RSV season. These high-risk children include those born preterm, with congenital heart disease, pulmonary abnormalities, neuromuscular disorders, and chromosomal differences. The AAP also recommends the 2026-2027 COVID-19 vaccine for all infants and children ages 6 through 23 months, as well as a single dose for children ages 2 through 18 with increased risk for severe COVID-19, regardless of prior vaccination status.
Brief written by urgent.news from Medical Xpress's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
